StockNews.com Upgrades MediWound (NASDAQ:MDWD) to “Sell”

MediWound (NASDAQ:MDWD) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research note issued on Wednesday.

Separately, HC Wainwright reiterated a “buy” rating and set a $28.00 price objective on shares of MediWound in a report on Friday, March 22nd.

MediWound Trading Down 0.2 %

Shares of MediWound stock opened at $17.71 on Wednesday. The company has a market cap of $168.10 million, a P/E ratio of -23.00 and a beta of 0.81. The business has a 50-day moving average price of $16.33 and a two-hundred day moving average price of $12.66. MediWound has a 1-year low of $7.10 and a 1-year high of $19.86.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Thursday, March 21st. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.04. The company had revenue of $5.34 million during the quarter, compared to the consensus estimate of $5.33 million. MediWound had a negative net margin of 35.94% and a negative return on equity of 20.22%. Equities research analysts forecast that MediWound will post -1.93 EPS for the current fiscal year.

Hedge Funds Weigh In On MediWound

A number of large investors have recently modified their holdings of MDWD. Essex Investment Management Co. LLC raised its holdings in MediWound by 241.6% during the first quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock worth $1,888,000 after buying an additional 93,705 shares during the last quarter. Yelin Lapidot Holdings Management Ltd. raised its holdings in shares of MediWound by 45.7% in the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock worth $1,276,000 after acquiring an additional 39,348 shares during the last quarter. Sargent Investment Group LLC lifted its position in MediWound by 7.0% in the 4th quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock valued at $1,111,000 after acquiring an additional 7,125 shares in the last quarter. Silverberg Bernstein Capital Management LLC lifted its position in MediWound by 7.8% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock valued at $1,214,000 after acquiring an additional 6,200 shares in the last quarter. Finally, Janney Montgomery Scott LLC bought a new stake in MediWound during the 1st quarter worth approximately $427,000. 46.83% of the stock is currently owned by institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.